De novo non-alcoholic fatty liver disease (NAFLD) in liver-transplanted patients for cirrhosis not due to non-alcoholic steatohepatitis (NASH) is becoming a growing phenomenon.
Dr Leo and colleagues performed a systematic review and evaluated the prevalence of this event and possible associated factors.
The team performed a literature search in medical databases in 2017.
Relevant publications were identified in most important databases.
The research team estimated the pooled prevalence of NAFLD and NASH in patients with liver transplant.
The team selected 12 studies, enrolling 2166 subjects overall undergoing post-liver transplant biopsy.
|The pooled weighted prevalence of de novo NAFLD was 26%|
|Alimentary Pharmacology & Therapeutics|
The pooled weighted prevalence of de novo NAFLD was 26%.
The researchers found that the pooled weighted prevalence of NASH was 2%.
The team noted that the highest prevalences of de novo NAFLD were found for patients transplanted for alcoholic cirrhosis, and cryptogenic cirrhosis, and for patients taking tacrolimus.
Tacrolimus showed a risk of NAFLD similar to ciclosporin.
Dr Leo's team concludes, "Patients undergoing liver transplant are more prone to experience diabetes, hypertension or dyslipidemia, and NAFLD may be an important element in this context."
"In this study, we show how the prevalence of NASH tends to remain significant and similar to the general population."
"Moreover, this study suggests a possible association with specific transplant indications."
"Further studies are required to confirm these findings."